^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SMART 102
i
Other names: SMART 102, Human T Lymphoid Progenitor (HTLP) injection, human T lymphoid progenitor cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Public Assistance - Paris Hospitals, Smart Immune
Drug class:
Cell therapy
Related drugs:
4ms
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients with Hematologic Malignancies (HTLP-ONCO) (clinicaltrials.gov)
P1/2, N=10, Recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Feb 2026 --> Aug 2027 | Trial primary completion date: May 2024 --> Nov 2025
Trial completion date • Trial primary completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • CD4 (CD4 Molecule) • CD7 (CD7 Molecule)
|
SMART 102
1year
Human Pro-T-Cell Manufacturing in Vitro Is a Safe Procedure for Hematopoietic Stem Cell Transplantation with Delayed T-Cell Reconstitution: Interim Results from 2 Different Clinical Trials (ASH 2023)
The GMP generation of Human T lymphoid Progenitors (HTLP) that are competent to rapidly become in vivo differentiated functional and thymic-educated T-cells may overcome the post-transplant delayed immune reconstitution... First infusions of HTLP in both clinical trials confirmed the safety and reproducible GMP manufacturing. HLTP offers an exciting perspective for improving immune reconstitution in alternative hematopoietic transplants.
Preclinical
|
CD34 (CD34 molecule) • CD7 (CD7 Molecule)
|
SMART 102
Share via
